Anthropic has announced a $10 million CAD investment in Canadian AI research, partnering with institutions such as Amii, Mila, and the Vector Institute. The funding will support research into responsible AI applications, with Claude credits provided to advance work in areas like AI trust and safety. This initiative highlights Canada's ongoing influence in AI development and its commitment to leading in AI governance. The investment also includes support for Canadian startups through the Anthropic for Startups program.
Read original
© SiftedNeko Health has successfully raised $700 million in Series C funding, marking a pivotal moment for the company. With 100,000 members and profitability at the clinic level, this funding round is a testament to the company's robust growth and operational success. The investment is set to drive further expansion and innovation in their healthcare services, potentially reshaping the landscape of healthcare delivery. Neko Health's strategic position in the health tech industry is strengthened by this substantial financial backing, which reflects strong investor belief in its business model and future trajectory.
© SiftedMeticulous, a London-based startup, has secured $15 million in Series A funding to advance its AI-driven code testing platform. Founded by ex-Palantir and Dropbox engineers, the company aims to streamline the process of verifying AI-generated code by simulating user flows and identifying edge cases. This approach allows developers to quickly understand the impact of code changes, potentially accelerating the deployment process. With plans to expand into backend testing and grow its team, Meticulous is positioning itself as a key player in the AI code verification space.
© TechCrunch AIMiles Wang, an OpenAI researcher, is reportedly leaving to start a new AI-driven drug discovery company, potentially valued at $2 billion. This move highlights the growing trend of applying AI to accelerate breakthroughs in life sciences, with Wang's startup aiming to repurpose existing drugs for new uses. While the funding details are still in flux, the interest from investors like Lightspeed shows the potential impact of AI in the pharmaceutical industry. If successful, Wang's venture could significantly reduce the time and cost associated with bringing new treatments to market.